Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HSD17B14 | Q9BPX1 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.42 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.42 |
| ▸ | HTR3B | O95264 | 3/20 | 0.42 |
| ▸ | HTR3A | P46098 | 3/20 | 0.42 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.42 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.39 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.39 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3466177 | 0.95 | HSD17B14 (0.49) | USP2MAPK1SMN1; SMN2HSD17B14KMT2A | |
| Hydrochloric Acid SCHEMBL4297856 | 0.94 | HSD17B14 (0.48) | USP2MAPK1SMN1; SMN2HSD17B14KMT2A | |
| SCHEMBL3467150 | 0.89 | HSD17B14 (0.50) | USP2MAPK1SMN1; SMN2HSD17B14KMT2A | |
| SCHEMBL3466779 | 0.88 | HSD17B14 (0.49) | USP2MAPK1SMN1; SMN2HSD17B14KMT2A | |
| SCHEMBL3467772 | 0.87 | HSD17B14 (0.48) | USP2MAPK1SMN1; SMN2HSD17B14KMT2A | |
| SCHEMBL4304173 | 0.86 | HSD17B14 (0.47) | USP2MAPK1SMN1; SMN2HSD17B14KMT2A | |
| SCHEMBL4305205 | 0.85 | HSD17B14 (0.51) | USP2MAPK1SMN1; SMN2HSD17B14PRKCQ | |
| SCHEMBL3466796 | 0.84 | HSD17B14 (0.53) | USP2MAPK1SMN1; SMN2HSD17B14PRKCQ | |
| SCHEMBL4290478 | 0.82 | HSD17B14 (0.48) | USP2MAPK1SMN1; SMN2HSD17B14KMT2A | |
| SCHEMBL3470360 | 0.82 | HSD17B14 (0.48) | USP2MAPK1SMN1; SMN2HSD17B14PRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2265600-A1 | PYRIDINYL AMIDES FOR THE TREATMENT OF CNS AND METABOLIC DISORDERS | Pfizer Inc. (US) | 2010-12-29 | — | — | EP | claimed |
| WO-2009098576-A1 | PYRIDINYL AMIDES FOR THE TREATMENT OF CNS AND METABOLIC DISORDERS | PFIZER INC. (US) | 2009-08-13 | — | — | WO | claimed |
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | PFIZER INC. | 2009-08-06 | — | — | US | claimed |
| EP-2265600-A1 | PYRIDINYL AMIDES FOR THE TREATMENT OF CNS AND METABOLIC DISORDERS | Pfizer Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009098576-A1 | PYRIDINYL AMIDES FOR THE TREATMENT OF CNS AND METABOLIC DISORDERS | PFIZER INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | PFIZER INC. | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | HTR6, HTR5A, TPH1 | USP2 4670/4885MAPK1 1674/4885SMN1; SMN2 2107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.